Skip to main content
. Author manuscript; available in PMC: 2015 Mar 31.
Published in final edited form as: Addict Biol. 2014 Feb 9;20(2):285–296. doi: 10.1111/adb.12122

Figure 2.

Figure 2

Administration of the mGluR1 antagonist YM 298198 or the mGluR5 antagonist MPEP into the accumbens core attenuated cocaine, but not sucrose, seeking. (a) Rats were administered vehicle, 5.0 or 50.0 μM YM 298198 into the accumbens core 10 minutes prior to a priming injection of cocaine (10 mg/kg, i.p.) during the reinstatement phase (n = 13/treatment). *P < 0.05 for active lever responding between vehicle and 50.0 μM YM 298198 (Bonferroni). (b) No differences in total active or inactive lever responses (mean ± SEM) during sucrose reinstatement test sessions following intra-accumbens core administration of vehicle or 50.0 μM YM 298198 (n = 9) were observed (unpaired t-tests, P > 0.05). (c) Total active and inactive lever responses (mean ± SEM) during the reinstatement test session following a 10 mg/kg priming injection of cocaine in rats pretreated with intra-accumbens core vehicle, 0.9 or 9.0 μM MPEP (n = 15/treatment). *P < 0.05 for active lever responding between vehicle and 9.0 μM MPEP (Bonferroni). (d) No significant differences in responding on the active or inactive levers (mean ± SEM) were found between treatments following intra-accumbens core administration of vehicle or 9.0 μM MPEP (n = 8) during sucrose reinstatement test sessions (unpaired t-tests, P > 0.05)